MX2020014290A - Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. - Google Patents

Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.

Info

Publication number
MX2020014290A
MX2020014290A MX2020014290A MX2020014290A MX2020014290A MX 2020014290 A MX2020014290 A MX 2020014290A MX 2020014290 A MX2020014290 A MX 2020014290A MX 2020014290 A MX2020014290 A MX 2020014290A MX 2020014290 A MX2020014290 A MX 2020014290A
Authority
MX
Mexico
Prior art keywords
vitokine
moiety
tissue
domain
bioactivatable
Prior art date
Application number
MX2020014290A
Other languages
English (en)
Inventor
Jing Xu
Yue- Sheng LI
Lingyun Rui
Original Assignee
Cugene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cugene Inc filed Critical Cugene Inc
Publication of MX2020014290A publication Critical patent/MX2020014290A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente exposición proporciona una plataforma de construcción de fármaco bioactivable en base a citosinas ("VitoKine") que tiene como objetivo reducir las toxicidades en base a los mecanismos sistémicos y conducir a una utilidad terapéutica más amplia para proteínas y citocinas tales como IL-15 e IL-2 para el tratamiento de cáncer, enfermedades autoinmunes, enfermedades inflamatorias, infecciones virales, trasplantes y varios otros trastornos. Las nuevas construcciones de VitoKine de la presente invención comprenden: 1) un dominio D1 ("D1") de la fracción dirigida sitio del tejido o enfermedad, 2) un dominio D2 ("D2") de la fracción bioactivable y un dominio D3 ("D3") de la fracción de ocultamiento. Es importante destacar que, debido a que la "fracción activa" de la construcción de VitoKine permanecerá inerte hasta que se active localmente mediante proteasas que se regulan positivamente en los tejidos enfermos, esto limitará la unión de la fracción activa a los receptores o los objetivos en la superficie periférica o en el celular de células y tejidos no enfermos para evitar la sobre-activación de la Vía y reducir las toxicidades indeseables" en el objetivo" "fuera del tejido". Además, la inercia de la fracción activa de VitoKine antes de la activación por la proteasa disminuirá significativamente el antígeno potencial o el decaimiento del objetivo y, por lo tanto, prolongará la vida media in vivo y dará como resultado una biodistribución, biodisponibilidad y eficacia terapéutica mejoradas.
MX2020014290A 2018-06-22 2019-06-20 Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. MX2020014290A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862689053P 2018-06-22 2018-06-22
PCT/US2019/038229 WO2019246392A1 (en) 2018-06-22 2019-06-20 Cytokine-based bioactivatable drugs and methods of uses thereof

Publications (1)

Publication Number Publication Date
MX2020014290A true MX2020014290A (es) 2021-08-05

Family

ID=68984291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020014290A MX2020014290A (es) 2018-06-22 2019-06-20 Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.

Country Status (9)

Country Link
US (2) US11634467B2 (es)
EP (1) EP3810624A4 (es)
JP (1) JP7477885B2 (es)
KR (1) KR20210038548A (es)
CN (1) CN112654633A (es)
AU (2) AU2019288484B2 (es)
CA (1) CA3102823A1 (es)
MX (1) MX2020014290A (es)
WO (1) WO2019246392A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
KR20210021468A (ko) 2018-05-14 2021-02-26 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩타이드 및 이의 사용 방법
AU2019271148B2 (en) 2018-05-14 2023-07-06 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
BR112021005907A2 (pt) 2018-09-27 2021-08-10 Xilio Development, Inc. citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
WO2020232305A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2021016599A1 (en) * 2019-07-25 2021-01-28 Trutino Biosciences Inc Il-2 cytokine prodrugs comprising a cleavable linker
WO2021097376A1 (en) 2019-11-14 2021-05-20 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
KR20220115611A (ko) * 2019-12-13 2022-08-17 큐진 인크. 사이토카인-기반 생체활성 약물 및 이의 사용 방법
JP2023510115A (ja) 2019-12-20 2023-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規ｉｌ２アゴニストおよびそれらの使用方法
WO2021142471A1 (en) * 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
IL294617A (en) * 2020-01-15 2022-09-01 Trutino Biosciences Inc Cytokine 2-il prodrugs involving a cleavable linker
MX2022011676A (es) * 2020-03-23 2023-03-08 Zymeworks Bc Inc Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
US20230226202A1 (en) * 2020-03-30 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Il-2/il15 compositions and methods of use thereof
EP3889183A1 (en) * 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
US20230159603A1 (en) * 2020-04-01 2023-05-25 Xilio Development, Inc. Masked il-12 cytokines and their cleavage products
EP4133085A1 (en) 2020-04-10 2023-02-15 CytomX Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
EP4204009A4 (en) * 2020-08-28 2024-10-09 Shanghai Junshi Biosciences Co Ltd USE OF AN ANTI-PD-1 ANTIBODY AND A CYTOTOXIC ANTICANCER IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
US20230357344A1 (en) * 2020-09-16 2023-11-09 Beigene, Ltd. Interleukin 15 Constructs and Methods of Use
EP4232071A4 (en) 2020-10-23 2024-08-28 Asher Biotherapeutics Inc FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
WO2022165443A1 (en) * 2021-02-01 2022-08-04 AskGene Pharma, Inc. Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
WO2022170063A1 (en) * 2021-02-05 2022-08-11 Salubris Biotherapeutics, Inc. Il-15 fusion proteins and methods of making and using same
BR112023018735A2 (pt) 2021-03-16 2023-11-28 Cytomx Therapeutics Inc Construtos de citocinas ativáveis mascarados e composições e métodos relacionados
AU2022292592A1 (en) * 2021-06-17 2024-01-25 Fuse Biosciences (Hong Kong) Limited Immunoconjugate molecules and related methods and compositions thereof
KR20240070507A (ko) * 2021-07-21 2024-05-21 트루티노 바이오사이언시스 인코포레이티드 링커 폴리펩타이드
AU2023226005A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
US20230382969A1 (en) * 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2024054424A1 (en) * 2022-09-08 2024-03-14 Cugene Inc. Novel pd1-targeted il-2 immunocytokine and vitokine fusions
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US7468352B1 (en) 1999-09-24 2008-12-23 The United States Of America As Represented By The Department Of Health And Human Services Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
WO2003048334A2 (en) 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2005085282A1 (en) 2004-02-27 2005-09-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
NZ599338A (en) 2007-06-27 2013-11-29 Marinepolymer Tech Inc Complexes of il-15 and il-15ralpha and uses thereof
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
JP5861223B2 (ja) 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
WO2011123683A2 (en) 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
KR102070098B1 (ko) 2010-09-21 2020-01-28 알토 바이오사이언스 코포레이션 다량체성 아이엘 15 용해성 융합 분자 및 그의 제조 및 사용 방법
NZ630790A (en) 2012-10-24 2016-11-25 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
RU2689717C2 (ru) 2014-01-08 2019-05-28 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Гетеродимерный белок il-15 и его применения
EP3174974B1 (en) 2014-07-29 2020-05-20 Novartis AG Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
WO2016077505A2 (en) 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
JP6709456B2 (ja) 2014-12-19 2020-06-17 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． インターロイキン１５タンパク複合体およびそれらの用途
SG11201807548SA (en) * 2016-03-08 2018-09-27 Maverick Therapeutics Inc Inducible binding proteins and methods of use
EP3430055B1 (en) * 2016-03-17 2020-10-28 Oslo Universitetssykehus HF Fusion proteins targeting tumour associated macrophages for treating cancer
CN108884170A (zh) 2016-03-22 2018-11-23 豪夫迈·罗氏有限公司 蛋白酶活化的t细胞双特异性分子
RU2019114175A (ru) 2016-10-14 2020-11-16 Ксенкор, Инк. Биспецифические гетеродимерные слитые белки, содержащие fc-слитые белки il-15/il-15ra и фрагменты антитела к pd-1
JP7268005B2 (ja) 2017-09-08 2023-05-02 武田薬品工業株式会社 拘束され、条件的に活性化された結合タンパク質
AU2019271148B2 (en) 2018-05-14 2023-07-06 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
BR112021005907A2 (pt) 2018-09-27 2021-08-10 Xilio Development, Inc. citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit

Also Published As

Publication number Publication date
CN112654633A (zh) 2021-04-13
CA3102823A1 (en) 2019-12-26
US20240141005A1 (en) 2024-05-02
EP3810624A1 (en) 2021-04-28
WO2019246392A1 (en) 2019-12-26
JP7477885B2 (ja) 2024-05-02
US20210139553A1 (en) 2021-05-13
EP3810624A4 (en) 2022-07-06
US11634467B2 (en) 2023-04-25
AU2019288484B2 (en) 2024-06-20
AU2019288484A1 (en) 2021-01-21
AU2024219567A1 (en) 2024-10-03
JP2021528493A (ja) 2021-10-21
KR20210038548A (ko) 2021-04-07

Similar Documents

Publication Publication Date Title
MX2020014290A (es) Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
MX2022007202A (es) Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
Lu et al. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy
MY167123A (en) Conveniently implantable sustained release drug compositions
CY1109333T1 (el) 3-[4- ετεροκυκλυλ-1,2,3-τριαζολ-1-υλ]-ν-αρυλο-βενζαμιδια ως αναστολεις της παραγωγης κυτοκινων για τη θεραπευτικη αγωγη χρονιων φλεγμονωδων νοσων
GB2448255A (en) Compositions and methods relating to treatment of cancer and infectious diseases
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
MY145329A (en) Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
GT200500363A (es) 3-amino-pirazol [3,4b] piridinas con inhibidores de proteintirosinquinasas, su preparacion y uso como medicamento.
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE485072T1 (de) Katheter mit distaler wirkstofffreisetzungseinheit
GT200500359A (es) Compuestos organicos
ATE256672T1 (de) 4,5-diaryl-3(2h)-furanon derivate als cyclooxygenase-2 inhibitoren
EA201000424A1 (ru) Антитела к il-23
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
BRPI0514735A (pt) derivados de piridino sulfonamida como moduladores do receptor de quimiocina
NO330984B1 (no) Aminosyre-fenoksyestere, fremgangsmate for fremstilling av slike, mellomprodukter i synteseveien, farmasoytisk preparat omfattende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom
EA202092459A1 (ru) Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают
YU55203A (sh) Konjugati jedinjenja specifičnog makrolida imunske ćelije sa anti-inflamatornim jedinjenjima, za poboljšano ćelijsko ciljanje u anti-inflamatornoj terapiji
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
EA201892443A1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen